Peripheral Artery Disease: Long-term Survival & Outcomes Study (PEARLS)
Peripheral Artery Disease: Long-term Survival & Outcomes Study (PEARLS)
批准号:
10744868
负责人:
Saket Girotra
金额:
$46.1万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-20 至 2023-08-31
中文摘要
项目总结/文摘
英文摘要
Project Summary/Abstract
Background: Peripheral artery disease (PAD) is a common and highly morbid condition. Nearly 25% of patients
die within 3 years of diagnosis, likely due to a high incidence of cardiovascular (CV) events: myocardial infarction
(MI) or stroke. A significantly larger proportion experience disability due to leg pain, poor mobility and amputation.
The cost of PAD-related hospital care alone exceeds $21 billion. However, research regarding long-term survival,
CV, and limb outcomes in PAD and the impact of existing treatments remain limited in large part due to the poor
accuracy of PAD diagnosis codes. Our team has developed a novel approach using natural language processing
(NLP) to identify PAD patients with a high degree of accuracy within the Veterans Health Administration (VHA).
Significance: The Peripheral Artery Disease: Long-term Survival & Outcomes Study (PEARLS) study will
advance scientific knowledge for PAD in several ways. We will use our NLP tool to assemble one of the largest
cohorts of PAD in the world and follow them long-term to assess the trajectory of survival and clinical outcomes,
evaluate utilization of recommended treatments (medications, risk factor control and revascularization) and the
association of above treatments with the above outcomes. Collectively, our work will address important gaps in
PAD research and yield insights regarding strategies to improve care delivery in this high-risk population.
Innovation: The use of an informatics-based method to assemble a cohort of newly diagnosed PAD patients in
a large integrated health system is highly innovative. We believe that our approach for cohort identification will
be transformational and promote big data analytics for research, improving care delivery, and future clinical trials.
Specific Aims: A1. Develop a national cohort of Veterans with newly diagnosed PAD using a novel NLP
algorithm. A2. Examine patterns of medical and invasive management and determine patient- and facility-level
correlates. A3. Determine the impact of medical and invasive management of PAD on long-term outcomes.
Methodology: We will implement our NLP algorithm to identify patients with new PAD diagnosis in VHA during
2015-2020 and obtain data on clinical and treatment related variables. We will follow our cohort longitudinally for
mortality, CV events (MI, stroke) and limb events (amputation). We will examine utilization of PAD treatments
and risk factor control, identify patient-level and hospital-level predictors of treatment using multi-level models.
We will use discrete survival models to evaluate the association of PAD treatments with long-term outcomes.
Implementation/Next Steps: Key deliverables will include a) an understanding of which patient groups are at
greatest risk for mortality and adverse outcomes; (b) determining the relative impact of PAD treatments on long-
term outcomes which can be useful for decision-making and c) an assessment of site-level variation in treatment
patterns. We envision that our findings will help us develop comprehensive disease management program to
improve quality of care and reduce disparities in use of effective treatments.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Achieving Equity in Hospital Performance Assessments Using Composite Race-Specific Measures of Risk-Standardized Readmission and Mortality Rates for Heart Failure.
使用针对心力衰竭的风险标准化再入院率和死亡率的复合种族特定指标,实现医院绩效评估的公平性。
DOI:
10.1161/circulationaha.122.061995
发表时间:
2023
期刊:
Circulation
影响因子:
37.8
作者:
[Mentias,Amgad, Peterson,EricD, Keshvani,Neil, Kumbhani,DharamJ, Yancy,ClydeW, Morris,AlannaA, Allen,LarryA, Girotra,Saket, Fonarow,GreggC, Starling,RandallC, Alvarez,Paulino, Desai,MilindY, Cram,Peter, Pandey,Ambarish]
通讯作者:
Pandey,Ambarish
Prognostic Significance of Newly Diagnosed Atrial Fibrillation After Acute Myocardial Infarction: A Study of 184,980 Medicare Patients.
急性心肌梗死后新诊断心房颤动的预后意义:对 184,980 名医疗保险患者的研究。
DOI:
10.1016/j.carrev.2022.06.258
发表时间:
2022
期刊:
Cardiovascular revascularization medicine : including molecular interventions
影响因子:
--
作者:
[Ayinde,Hakeem, Riedle,Benjamin, Ojo,Amole, Abugroun,Ashraf, Girotra,Saket, Polgreen,Linnea]
通讯作者:
Polgreen,Linnea
DOI:
10.1161/jaha.123.029971
发表时间:
2023-09-19
期刊:
JOURNAL OF THE AMERICAN HEART ASSOCIATION
影响因子:
5.4
作者:
[Krittanawong, Chayakrit, Khawaja, Muzamil, Tamis-Holland, Jacqueline E., Girotra, Saket, Rao, Sunil V.]
通讯作者:
Rao, Sunil V.
DOI:
10.1161/circoutcomes.122.009042
发表时间:
2022-10
期刊:
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
影响因子:
6.9
作者:
[Chan, Paul S., McNally, Bryan, Chang, Anping, Girotra, Saket, Al-Araji, Rabab, Mawani, Minaz, Ahn, Ki Ok, Merritt, Robert]
通讯作者:
Merritt, Robert
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
心血管疾病患者的肠涂层与未涂层的阿司匹林的有效性和安全性:对适应性随机临床试验的次要分析。
DOI:
10.1001/jamacardio.2023.3364
发表时间:
2023-11-01
期刊:
JAMA CARDIOLOGY
影响因子:
24
作者:
[Sleem, Amber, Effron, Mark B., Stebbins, Amanda, Wruck, Lisa M., Marquis-Gravel, Guillaume, Munoz, Daniel, Re, Richard N., Gupta, Kamal, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, Whittle, Jeffrey, Benziger, Catherine P., Farrehi, Peter M., Knowlton, Kirk U., Polonsky, Tamar S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Jones, W. Schuyler, Hernandez, Adrian F.]
通讯作者:
Hernandez, Adrian F.
共 15 条
Peripheral Artery Disease: Long-term Survival & Outcomes Study (PEARLS)
-
批准号:10734991
-
项目类别:
-
资助金额:$68.03万
-
财政年份:2023
-
负责人:Saket Girotra
-
依托单位:
Peripheral Artery Disease: Long-term Survival & Outcomes Study (PEARLS)
-
批准号:10275610
-
项目类别:
-
资助金额:$17.21万
-
财政年份:2021
-
负责人:Saket Girotra
-
依托单位:
Post-Resuscitation Care and Survival After In-hospital Cardiac Arrest
-
批准号:8679133
-
项目类别:
-
资助金额:$12.55万
-
财政年份:2014
-
负责人:Saket Girotra
-
依托单位:
海外基金